- Home
- CMPO vs AUPH Comparison
CMPO vs AUPH Comparison
Compare CMPO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPO
- AUPH
- Stock Information
- Founded
- CMPO 2000
- AUPH 1993
- Country
- CMPO United States
- AUPH Canada
- Employees
- CMPO N/A
- AUPH N/A
- Industry
- CMPO Finance: Consumer Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CMPO Finance
- AUPH Health Care
- Exchange
- CMPO Nasdaq
- AUPH Nasdaq
- Market Cap
- CMPO 1.5B
- AUPH 1.3B
- IPO Year
- CMPO N/A
- AUPH 1999
- Fundamental
- Price
- CMPO $15.28
- AUPH $8.77
- Analyst Decision
- CMPO Strong Buy
- AUPH Strong Buy
- Analyst Count
- CMPO 8
- AUPH 3
- Target Price
- CMPO $16.81
- AUPH $10.33
- AVG Volume (30 Days)
- CMPO 885.2K
- AUPH 1.3M
- Earning Date
- CMPO 11-08-2024
- AUPH 02-13-2025
- Dividend Yield
- CMPO N/A
- AUPH N/A
- EPS Growth
- CMPO N/A
- AUPH N/A
- EPS
- CMPO N/A
- AUPH N/A
- Revenue
- CMPO $419,612,000.00
- AUPH $220,361,000.00
- Revenue This Year
- CMPO $10.30
- AUPH $36.97
- Revenue Next Year
- CMPO $6.26
- AUPH $16.43
- P/E Ratio
- CMPO N/A
- AUPH N/A
- Revenue Growth
- CMPO 9.13
- AUPH 38.72
- 52 Week Low
- CMPO $4.61
- AUPH $4.71
- 52 Week High
- CMPO $17.03
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CMPO 41.55
- AUPH 45.91
- Support Level
- CMPO $15.26
- AUPH $8.89
- Resistance Level
- CMPO $16.58
- AUPH $9.31
- Average True Range (ATR)
- CMPO 0.62
- AUPH 0.34
- MACD
- CMPO -0.14
- AUPH -0.11
- Stochastic Oscillator
- CMPO 6.91
- AUPH 1.43
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.